Skip to main content
  • Book
  • © 1998

Angiotensin II Receptor Blockade Physiological and Clinical Implications

Part of the book series: Progress in Experimental Cardiology (PREC, volume 2)

Buy it now

Buying options

eBook USD 259.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

This is a preview of subscription content, log in via an institution to check for access.

Table of contents (42 chapters)

  1. Front Matter

    Pages i-xliii
  2. Pharmacological Interruption of Renin-Angiotensin in Hypertension

    1. Front Matter

      Pages 1-1
    2. The Brain Renin-Angiotensin System And Salt-Sensitive Hypertension

      • Shereeni J. Veerasingham, Frans H.H. Leenen
      Pages 15-32
    3. Cellular Physiology of Angiotensin II Receptors in Vascular Smooth Muscle Cells

      • P. Zahradka, D. Wilson, L. Saward, L. Yau, P. K. Cheung
      Pages 41-50
    4. Comparison of the Inhibitory Actions of Angiotensin AT1 Receptor Antagonists in the Peripheral Vascular Bed

      • Hunter C. Champion, David G. Lambert, Trinity J. Bivalacqua, Dennis B. Mcnamara, Philip J. Kadowitz
      Pages 65-86
  3. Angiotensin Blockade and Cardiovascular Disease

    1. Front Matter

      Pages 127-127
    2. Angiotensin II Receptors AT1 and AT2: New Mechanisms of Signaling And Antagonistic Effects of AT1 and AT2

      • Tadashi Inagami, Satoru Eguchi, Satoshi Tsuzuki, Toshihiro Ichiki
      Pages 129-139
    3. Angiotensin Receptor Antagonists and Cardiovascular Remodeling

      • K. Sabri, C. Chassagne, B. Lévy, J.L. Samuel, L. Rappaport
      Pages 141-151
    4. Functional Analysis of Tissue Renin-Angiotensin System Using “Gain and Loss of Function” Approaches: In Vivo Test of in Vitro Hypothesis

      • Ryuichi Morishita, Motokuni Aoki, Hidetsugu Matsushita, Shin-Ichiro Hayashi, Shigefumi Nakamura, Nobuaki Nakano et al.
      Pages 163-174
    5. Role of Cytokines in Septic Cardiomyopathy

      • Ursula Müller-Werdan, Heike Schumann, Ralph Fuchs, Harald Loppnow, Christopher Reithmann, Susann Koch et al.
      Pages 185-219
    6. In Pursuit of Optimal Care and Outcomes for Patients with Congestive Heart Failure: Insights from the Past Decade

      • Terrence Montague, Koon Teo, Laurel Taylor, Finlay McAlister, Margaret Ackman, Ross Tsuyuki
      Pages 221-232

About this book

The relationship between angiotensin II and hypertension was established in 1898 when angiotensin II was shown to modulate systemic blood pressure. Over the intervening decades, a complete characterization of the renin-angiotensin system (RAS) has been achieved, and our understanding of its biochemistry and physiology has led to the directed development of agents such ·as ACE inhibitors and receptor antagonists capable of controlling hypertension. More recently, it was shown that angiotensin II is secreted within certain tissues and that these tissue-specific systems operate independently of the systemic RAS. The novel concept that angiotensin II regulates a number of cardiovascular processes that are unrelated to blood pressure has renewed the interest of both basic and clinical scientists in angiotensin II. The association between angiotensin II and cardiac growth, in particular, has indicated that therapies currently in use for hypertension may have direct application to the treatment of heart failure. The Manitoba Cardiovascular Forum on Angiotensin Receptor Blockade in Winnipeg was convened October 18-20, 1996 to examine the clinical and basic aspects of angiotensin receptor biology as they apply to hypertension and heart failure. In addition, the potential treatment of these conditions using specific angio­ tensin receptor antagonists was addressed within the context of their immediate therapeutic application and future potential.

Editors and Affiliations

  • Institute of Cardiovascular Sciences St. Boniface General Hospital Research Centre Faculty of Medicine, University of Manitoba, Winnipeg, Canada

    Naranjan S. Dhalla, Peter Zahradka, Ian M. C. Dixon, Robert E. Beamish

Bibliographic Information

  • Book Title: Angiotensin II Receptor Blockade Physiological and Clinical Implications

  • Editors: Naranjan S. Dhalla, Peter Zahradka, Ian M. C. Dixon, Robert E. Beamish

  • Series Title: Progress in Experimental Cardiology

  • DOI: https://doi.org/10.1007/978-1-4615-5743-2

  • Publisher: Springer New York, NY

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer Science+Business Media New York 1998

  • Hardcover ISBN: 978-0-7923-8147-1Published: 31 October 1998

  • Softcover ISBN: 978-1-4613-7631-6Published: 13 October 2012

  • eBook ISBN: 978-1-4615-5743-2Published: 06 December 2012

  • Series ISSN: 1389-1774

  • Edition Number: 1

  • Number of Pages: XLIII, 588

  • Topics: Cardiology

Buy it now

Buying options

eBook USD 259.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access